News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Sarepta Therapeutics, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Genetown
Sarepta Jumps Despite DMD Safety Issues in FDA Database
October 3, 2017
·
2 min read
Policy
Sarepta’s Exondys 51 Saga Continues as More Details About FDA’s Criticism Uncovered
August 22, 2017
·
3 min read
Policy
FDA Docs Reveal CDER Chief Skirted Procedures Approving Sarepta’s Controversial Drug Eteplirsen
August 3, 2017
·
1 min read
Deals
New Sarepta CEO’s M&A Experience Sparks Sale Speculation
June 30, 2017
·
3 min read
Business
Sarepta Taps Allergan Alum as New CEO
June 29, 2017
·
2 min read
Policy
Journalist Sues FDA for Documents Related to Sarepta’s DMD Drug
May 26, 2017
·
4 min read
Genetown
Can Sarepta Continue To Live Up To The DMD Hype?
May 8, 2017
·
1 min read
Deals
Sarepta Tests Biotech’s CEO Vacuum Hypothesis
May 2, 2017
·
1 min read
Deals
How Much Rumored Suitors Like Sanofi Would Have To Pay For Sarepta
May 2, 2017
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Business
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
July 28, 2021
·
1 min read
Genetown
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2021
June 30, 2021
·
2 min read
Genetown
Sarepta Therapeutics to Present at Upcoming Investor Conferences - June 03, 2021
June 3, 2021
·
1 min read
Business
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001
May 18, 2021
·
9 min read
Genetown
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
May 17, 2021
·
2 min read
Business
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
May 5, 2021
·
33 min read
Genetown
Sarepta Therapeutics to Present at Upcoming Investor Conferences - May 04, 2021
May 4, 2021
·
1 min read
Drug Development
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021
·
10 min read
Deals
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 30, 2021
April 30, 2021
·
2 min read
Genetown
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
April 30, 2021
·
2 min read
